MedTrace Logo

Iguratimod in Kidney Transplant Recipients

NCT02839941 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-29

No results posted yet for this study

Summary

The objective of the study is to evaluate the effect of iguratimod concomitant with conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly mismatched Kidney Transplant recipients.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Iguratimod

Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks

DRUG

Mycophenolate mofetil

All subjects will receive mycophenolate mofetil for consecutive 52 weeks

DRUG

Tacrolimus

All subjects will receive tacrolimus for consecutive 52 weeks

DRUG

Glucocorticoids

All subjects will receive glucocorticoids for consecutive 52 weeks

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Min Gu · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02839941 on ClinicalTrials.gov